Mometasone furoate with glycopyrronium bromide and indacaterol (Enerzair Breezhaler) - Asthma

You are here : Home > Formulary Search > Mometasone furoate with glycopyrronium bromide and indacaterol (Enerzair Breezhaler) - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Inhaler (dry powder)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

Restrictions / Comments :

Important

Specialist recommendation only. Used in severe asthma.

Only triple therapy DPI licensed for asthma.

Prescribe by BRAND

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Mometasone furoate with glycopyrronium bromide and indacaterol (Enerzair Breezhaler)

Indication :

Asthma

Group Name :

Triple therapy

Keywords :

ICS, Triple therapy, LABAs, adrenoreceptor agonists, bronchodilators, long acting beta 2 agonist, respiratory, muscarinic receptor antagonist

Brand Names Include :

Enerzair Breezhaler

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Asthma

Supporting Documents :

Other Indications

Below are listed other indications that Mometasone furoate with glycopyrronium bromide and indacaterol (Enerzair Breezhaler) is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (0)

No records returned.